Neil Aaronson
Overview
Explore the profile of Neil Aaronson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bjelic-Radisic V, Cardoso F, Weis J, Pogoda K, Arraras J, Greimel E, et al.
Breast
. 2025 Feb;
80:103890.
PMID: 39947087
Background: The EORTC QLQ-BR23, published in 1996, was one of the first disease-specific questionnaires to assess health-related quality of life (HRQoL) in patients with breast cancer (BC). In the last...
2.
Oort Q, Dirven L, Sikkes S, Aaronson N, Boele F, Brannan C, et al.
Neurooncol Pract
. 2022 Jul;
9(4):271-283.
PMID: 35855454
Background: Neurocognitive impairments are common among brain tumor patients, and may impact patients' awareness of performance in instrumental activities in daily life (IADL). We examined differences between patient- and proxy-reported...
3.
Coomans M, Dirven L, Aaronson N, Baumert B, van den Bent M, Bottomley A, et al.
Neuro Oncol
. 2022 Apr;
24(12):2159-2169.
PMID: 35404443
Background: Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be...
4.
Giesinger J, Efficace F, Aaronson N, Calvert M, Kyte D, Cottone F, et al.
Value Health
. 2021 Apr;
24(4):585-591.
PMID: 33840437
Objectives: In our systematic review, we assessed past and current practice of patient-reported outcome (PRO) measurement in cancer randomized, controlled trials (RCTs). Methods: We included RCTs with PRO endpoints evaluating...
5.
Oort Q, Dirven L, Sikkes S, Aaronson N, Boele F, Brannan C, et al.
Qual Life Res
. 2021 Jan;
30(5):1491-1502.
PMID: 33496902
Purpose: Being able to function independently in society is an important aspect of quality of life. This ability goes beyond self-care, requires higher order cognitive functioning, and is typically measured...
6.
Loppenthin K, Johansen C, Larsen M, Forchhammer B, Brennum J, Piil K, et al.
J Natl Compr Canc Netw
. 2020 Sep;
18(9):1222-1229.
PMID: 32886907
Background: It is well established that patients with glioma may experience adverse general (eg, headache) or focal symptoms (eg, personality changes) and neurocognitive deficits (eg, planning), but they may also...
7.
Efficace F, Cottone F, Sommer K, Kieffer J, Aaronson N, Fayers P, et al.
Value Health
. 2019 Nov;
22(11):1303-1310.
PMID: 31708068
Objectives: We investigated the validity of the recently developed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) summary score in patients with...
8.
Bouchard L, Aaronson N, Gondek K, Cella D
Expert Rev Qual Life Cancer Care
. 2019 Apr;
3(2-3):35-46.
PMID: 31020045
Introduction: A critical challenge in oncology is interpreting clinical trial results to inform clinical decision making. Clinical trials typically focus on overall survival (OS) and progression-free survival (PFS) as primary...
9.
Mikropoulos C, Hutten Selkirk C, Saya S, Bancroft E, Vertosick E, Dadaev T, et al.
Br J Cancer
. 2018 Mar;
118(6):e17.
PMID: 29509747
This corrects the article DOI: 10.1038/bjc.2017.429.
10.
Mikropoulos C, Hutten Selkirk C, Saya S, Bancroft E, Vertosick E, Dadaev T, et al.
Br J Cancer
. 2018 Jan;
118(2):266-276.
PMID: 29301143
Background: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a...